In Malta, off-label prescribing of medicines in children stands at 45%, mainly because of failure by prescribers to follow the dosing recommendations in the product literature. In addition, registration procedures of pharmaceuticals may inadvertently contribute to this high incidence of off-label prescribing.
Methods:
A literature review was conducted to identify regulatory provisions relating to the registration of medicines in Malta that could give rise to off-label use. Furthermore, the product literature of the 2 classes of medicines most commonly prescribed in children, antibiotics and respiratory medicines, were reviewed. This was done in order to gauge whether the different registration routes implemented in Malta to market these medicines could give rise to off-label use.
Results:
The national registration procedure relating to Article 126a of Directive 2001/83/EC and, to a lesser extent, line extensions, parallel importation, and the provision detailed in Article 11 of Directive 2001/83/EC were found to lead to discrepancies and potentially misleading inclusions in the product literature. These, in turn, may well contribute to off-label use of medicines in children.
Conclusions:
Off-label prescribing does not necessarily mean that efficacy and safety data are unavailable. Variances in the product literature of medicines having the same active ingredients but imported from different countries may cause divergent prescribing practices, leading to inadvertent off-label use. The various stakeholders, including member states such as Malta, should devise strategies to harmonize the most recent labeling information in order to support the safe and effective use of pediatric medicines, thereby decreasing off-label use.
Commission of the European Communities. Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal products. http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A31965L0065. Published 1965. Accessed May 2016.
Commission of the European Communities. Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products. http://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1462829026743&uri=CELEX:32008R1234. Published 2008. Accessed May 2016.
7.
Commission of the European Communities. Communication on parallel imports of proprietary medicinal products for which marketing authorisations have already been granted. COM(2003) 839 final. http://ec.europa.eu/health/files/eudralex/vol-1/com_2003_839/com_2003_839_en.pdf. Published December 30, 2003. Accessed May 2016.
EllulICGrechV. Off-label and unlicensed paediatric prescribing in a community setting: a prospective longitudinal cohort study in Malta. Paediatr Int Child Health. 2014;34:12–18.
Commission of the European Communities. Commission Regulation (EC) no 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. http://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1462830199210&uri=CELEX:32006R1901. Published 2006. Accessed May 2016.
15.
Commission of the European Communities. Better medicines for children from concept to reality. General report on experience acquired as a result of the application of Regulation (EC) No 1901/2006 on medicinal products for paediatric use. Report No: COM(2013) 443 final. http://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A52013DC0443. Published June 2013. Accessed May 2016.
16.
Morales-CarpiCEstañLRubioELurbeEMorales-OlivasFJ. Drug utilization and off-label drug use among Spanish emergency room paediatric patients. Eur J Clin Pharmacol. 2010;66:315–320.
17.
KimlandEOdlindV. Off-label drug use in pediatric patients. Clin Pharmacol Ther. 2012;91:796–801.
18.
EllulICGrechVAttard-MontaltoS. Paediatric off-label and unlicensed prescribing in primary care in Malta: prospective observational drug utilisation study. Int J Risk Saf Med. 2015;27:123–134.
19.
CarnovaleCContiVPerroneV. Paediatric drug use with focus on off-label prescriptions in Lombardy and implications for therapeutic approaches. Eur J Pediatr. 2013;172:1679–1685.
National Horizon Scanning Centre. New and emerging technology briefing. Tocilizumab (Actemra™) for rheumatoid arthritis and juvenile idiopathic arthritis. University of Birmingham; 2006.
22.
CumminsCConnockMFry-SmithABurlsA. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. Health Technol Assess. 2002;6:1–43.
23.
American Academy of Pediatrics Committee on Drugs. Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. Pediatrics. 1996;98:143–145.
24.
BavdekarSBGogtayNJ. Unlicensed and off-label drug use in children. J Postgrad Med. 2005;51:249–252.
25.
MarchettiFBuaJVenturaA. The awareness among paediatricians of off-label prescribing in children: a survey of Italian hospitals. Eur J Clin Pharmacol. 2007;63:81–85.
26.
CarnovaleCContiVPerroneV. Paediatric drug use with focus on off-label prescriptions in Lombardy and implications for therapeutic approaches. Eur J Pediatr. 2013;172:1679–1685.
27.
LassJIrsAPisarevHLeinemannTLutsarI. Off label use of prescription medicines in children in outpatient setting in Estonia is common. Pharmacoepidemiol Drug Saf. 2011;20:474–481.
28.
BazzanoATMangione-SmithRSchonlauMSuttorpMJBrookRH. Off-label prescribing to children in the United States outpatient setting. Acad Pediatr. 2009;9:81–88.
29.
MühlbauerBJanhsenKPichlerJSchoettlerP. Off-label use of prescription drugs in childhood and adolescence: an analysis of prescription patterns in Germany. Dtsch Arztebl Int. 2009;106:25–31.
30.
OlssonJKimlandEPetterssonSOdlindV. Paediatric drug use with focus on off-label prescriptions in Swedish outpatient care—a nationwide study. Acta Paediatr. 2011;100:1272–1275.
31.
RibeiroMJorgeAMacedoAF. Off-label drug prescribing in a Portuguese paediatric emergency unit. Int J Clin Pharm. 2013;35:30–36.
Maltese Medicines Authority. Authorisation in line with Article 126(a) of Directive 2001/83/EC. http://medicinesauthority.gov.mt/126a. Published 2016. Accessed May 2016.
36.
Matrix Insight. Study on the Availability of Medicinal Products for Human Use. http://ehtpa.eu/pdf/Matrix_report.pdf. Published December 2012. Accessed May 2016.
EU Secretariat. Ministry for European Affairs and Implementation of the Electoral Manifesto. Study on the Availability of Medicinal Products for Human Use. Feedback on the report by Matrix Insight, as applicable to Malta, based on the experience of the last ten years. http://ec.europa.eu/health/files/committee/73meeting/73plus/malta.pdf. Published March 2014. Accessed May 2016.
Commission of the European Communities. General report on experience acquired as a result of the application of the paediatric regulation (Article 50(2) of Regulation (EC) No 1901/2006). “Experience acquired and Lessons learnt” submitted for public consultation. Report No: SANCO/D5/FS/(2012)1251190. http://ec.europa.eu/health/files/paediatrics/2012-09_publicconsultation_en.pdf. Published September 2012. Accessed May 2016.
46.
Ekins-DaukesSHelmsPJSimpsonCRTaylorMWMcLayJS. Off-label prescribing to children in primary care: retrospective observational study. Eur J Clin Pharmacol. 2004;60:349–353.
